ProCE Banner Activity

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

Slideset

Download this slideset from a live meeting series for the multidisciplinary team to get up to date on the latest clinical data informing optimal use of TROP-2 antibody–drug conjugates in the treatment of advanced triple-negative breast cancer and HR-positive/HER2-negative metastatic breast cancer, including management of key adverse events associated with these agents.

Released: October 11, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.